Regional treatment of metastasis: Role of regional perfusion. State of the art isolated limb perfusion for limb salvage

Annals of Oncology

Volumn 15, Issue SUPPL. 4, 2004, Pages

  Eggermont, A M M ^a   Brunstein, F ^a   Grunhagen D ^a   ten Hagen, T L M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE DERIVATIVE; DACTINOMYCIN; DOXORUBICIN; GAMMA INTERFERON; HISTAMINE; MELPHALAN; N(G) NITROARGININE; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE SYNTHASE; TUMOR NECROSIS FACTOR ALPHA;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLISTER; CLINICAL TRIAL; DRUG POTENTIATION; DRUG UPTAKE; ENZYME INHIBITION; EPIDERMOLYSIS; ERYTHEMA; HUMAN; HYPERTHERMIA; LIMB AMPUTATION; LIMB PERFUSION; LIMB SALVAGE; LOW DRUG DOSE; LYMPH NODE METASTASIS; MELANOMA; META ANALYSIS; METASTASIS; NONHUMAN; PERIPHERAL EDEMA; PRIORITY JOURNAL; REGIONAL PERFUSION; SOFT TISSUE SARCOMA; TUMOR VASCULARIZATION;

ADULT; AGE FACTORS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; DOXORUBICIN; EXTREMITIES; HUMANS; MELANOMA; MELPHALAN; MIDDLE AGED; PATIENT SELECTION; SALVAGE THERAPY; SARCOMA; SKIN NEOPLASMS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 9744232910     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdh913     Document Type: Article

References (50)

1. Stotter AT, A'Hearn RP, Fisher C et al. The influence of local recurrence of extremity soft tissue sarcoma on metastasis and survival. Cancer 1990; 65: 1119-1129.
2. Gustafson P, Rööser B, Rydholm A. Is local recurrence of minor importance for metastases in soft tissue sarcoma? Cancer 1991; 67: 2083-2086.
3. Creech O, Krementz E, Ryan E, Winblad J. Chemotherapy of cancer: regional perfusion utilising an extracorporeal circuit. Ann Surg 1958; 148: 616-632.
4. Benckhuijsen C, Kroon BB, van Geel AN et al. Regional perfusion treatment with melphalan for melanoma in a limb: an evaluation of drug kinetics. Eur J Surg Oncol 1988; 14: 157-163.
5. Thompson JF, Gianoutsos MP. Isolated limb perfusion for melanoma - effectiveness and toxicity of cisplatin compared with that of melphalan and other drugs. World J Surg 1992; 16: 227-233.
6. Wieberdink K, Benckhuijsen C, Braat RP et al. Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions. Eur J Cancer Clin Oncol 1982; 18: 905-910.
7. Krementz ET, Carter RD, Sutherland CM, Hutton I. Chemotherapy of sarcomas of the limbs by regional perfusion. Ann Surg 1977; 185: 555-564.
8. Pommier RF, Moseley HS, Cohen J et al. Pharmacokinetics, toxicity, and short-term results of cisplatin hyperthermic isolated limb perfusion for soft tissue sarcoma and melanoma of the extremities. Am J Surg 1988; 155: 667-671.
9. Klaase JM, Kroon BBR, Benckhuysen C et al. Results of regional isolation perfusion with cytostatics in patients with soft tissue tumors of the extremities. Cancer 1989; 64: 616-621.
10. Rossi CR, Vecchiato A, Foletto M et al. Phase II study on neoadjuvant hyperthermic-antiblastic perfusion with doxorubicin in patients with intermediate or high grade limb sarcomas. Cancer 1994; 73: 2140-2146.
11. Lienard D, Ewalenko, Delmotte JJ et al. High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J Clin Oncol 1992; 10: 50-62.
12. Eggermont AMM, Liénard D, Schraffordt Koops H et al. Treatment of irresectable soft tissue sarcomas of the limbs by isolation perfusion with high dose TNF-α in combination with gamma-Interferon and melphalan. In Fiers W, Buurman WA (eds): Tumor Necrosis Factor: Molecular and Cellular Biology and Clinical Relevance. Basle: Karger Verlag 1993; 239-243.
13. Hill S, Fawcett WJ, Sheldon J et al. Low dose tumor necrosis factor-alpha and melphalan in hyperthermic isolated limb perfusion. Br J Surg 1993; 80: 995-997.
14. Eggermont AMM, Schraffordt Koops H, Lienard D et al. Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial. J Clin Oncol 1996; 14: 2653-2665.
15. Santinami M, Deraco M, Azzarelli A et al. Treatment of recurrent sarcoma of the extremities by isolated perfusion using tumor necrosis factor alpha and melphalan. Tumori 1996; 82: 579-584.
16. Eggermont AMM, Schraffordt Koops H, Klausner JM et al. Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience. Ann Surg 1996; 224: 756-764, discussion 764-765.
17. Gutman M, Inbar M, Lev-Shlush D et al. High dose tumor necrosis factor-α and melphalan administered via isolated limb perfusion for advanced limb soft tissue sarcoma results in a >90% response rate and limb preservation. Cancer 1997; 79: 1129-1137.
18. Eggermont AMM, Schraffordt Koops H, Klausner JM et al. Limb salvage by isolation limb perfusion with Tumor Necrosis Factor Alpha and melphalan for locally advanced extremity soft tissue sarcomas: results of 270 perfusions in 246 patients. Proc Am Soc Clin Oncol 1999; 11: 497 (Abstr).
19. Rossi CR, Foletto M, Di Filippo F et al. Soft tissue limb sarcomas: Italian clinical trials with hyperthermic antiblastic perfusion. Cancer 1999; 86: 1742-1749.
20. Lejeune FJ, Pujol N, Lienard D et al. Limb salvage by neoadjuvant isolated perfusion with TNFalpha and melphalan for non-resectable soft tissue sarcoma of the extremities. Eur J Surg Oncol 2000; 26: 669-678.
21. Hohenberger P, Kettelhack C, Hermann A, Schlag PM. Functional outcome after preoperative isolated limb perfusion with rhTNFalpha/Melphalan for high-grade extremity sarcoma. Eur J Cancer 2001; 37: S34-S35.
22. Lans TE, de Wilt JHW, van Geel AN, Eggermont AMM. Isolated limb perfusion with tumor necrosis factor and melphalan for nonresectable Stewart-Treves lymphangiosarcoma. Ann Surg Oncol 2002; 9: 1004-1009.
23. Noorda EM, Vrouwenraets BC, Nieweg OE et al. Isolated limb perfusion with TNFα and melphalan for irresectable soft tissue sarcoma of the extremities. Ann Surg Oncol 2003; 10: S36.
24. Bonvalot S, Lejeune F, Laplanche A et al. Limb salvage by isolated limb perfusion (iILP) in patients with locally advanced soft tissue sarcoma (ASTS): a randomized phase II study comparing 4 doses of TNFa. Proc Am Soc Clin Oncol 2003; 22: 823 (Abstr 3307).
25. Grünhagen D, Lans TE, de Wilt JHW et al. Management of local recurrences of soft tissue sarcomas in an irradiated field after prior surgery and radiotherapy: the role of TNF-based isolated limb perfusions to achieve limb salvage. Eur J Cancer Suppl 2003; 1: 699.
26. Etten van B, van Geel AN, de Wilt JHW, Eggermont AMM. Fifty tumor necrosis factor-based isolated limb perfusions for limb salvage in patients older than 75 years with limb-threatening soft tissue sarcomas and other extremity tumors. Ann Surg Oncol 2003; 27: 32-37.
27. Vrouwenraets BC, Kroon BBR, Ogilvie AC et al. Absence of severe systemic toxicity after leakage controlled isolated limb perfusion with Tumor Necrosis Factor alpha and melphalan. Ann Surg Oncol 1999; 6: 405-412.
28. Stam TC, Swaak AJ, de Vries MR et al. Systemic toxicity and cytokine/acute phase protein levels in patients after isolated limb perfusion with tumor necrosis factor-alpha complicated by high leakage. Ann Surg Oncol 2000; 4: 268-275.
29. Vrouenraets BC, Eggermont AMM, Hart AA et al. Regional toxicity after isolated limb perfusion with melphalan and tumour necrosis factor-alpha versus toxicity after melphalan alone. Eur J Surg Oncol 2001; 27: 390-395.
30. Lejeune FJ, Lienard D, Leyvraz S, Mirimanoff RO. Regional therapy of melanoma. Eur J Cancer 1993; 29A: 606-612.
31. Eggermont AMM, Liénard D, Schraffordt Koops H et al. High dose tumor necrosis factor-alpha in isolation perfusion of the limb: highly effective treatment for melanoma in transit metastases or unresectable sarcoma. Reg Cancer Treat 1995; 7: 32-36.
32. Eggermont AMM. Treatment of melanoma intransit metastases confined to the limb. Cancer Surv 1996; 26: 335-349.
33. Fraker DL, Alexander HR, Andrich M, Rosenberg SA. Treatment of patients with melanoma of the extremity using hyperthermic isolated limb perfusion with melphalan, tumor necrosis factor, and interferon gamma: results of a tumor necrosis factor dose-escalation study. J Clin Oncol 1996; 14: 479-489.
34. Lienard D, Eggermont AMM, Schraffordt Koops H et al. Isolated limb perfusion with tumour necrosis factor-alpha and melphalan with or without interferon-gamma for the treatment of in-transit melanoma metastases: a multicentre randomized phase II study. Melanoma Res 1999; 9: 491-502.
35. Olieman AF, Lienard D, Eggermont AMM et al. Hyperthermic isolated limb perfusion with tumor necrosis factor alpha, interferon gamma, and melphalan for locally advanced nonmelanoma skin tumors of the extremities: a multicenter study. Arch Surg 1999; 134: 303-307.
36. Bickels J, Manusama ER, Gutman M et al. Isolated limb perfusion with tumour necrosis factor-alpha and melphalan for unresectable bone sarcomas of the lower extremity. Eur J Surg Oncol 1999; 25: 509-514.
37. Lev-Chelouche D, Abu-Abeid S, Nakache R et al. Limb desmoid tumors: a possible role for isolated limb perfusion with tumor necrosis factor-alpha and melphalan. Surgery 1999; 126: 963-967.
38. Grünhagen DJ, Brunstein F, Graveland WJ et al. 100 consecutive isolated limb perfusions with TNF-α and melphalan in melanoma patients with multiple intransit metastases. Ann Surg 2004; In press.
39. 31P magnetic resonance spectroscopy as predictor for clinical response in human extremity sarcomas treated by single dose TNFα + melphalan isolated limb perfusion. NMR Biomed 1995; 18: 215-224.
40. Renard N, Liénard D, Lespagnard L et al. Early endothelium activation and polymorphonuclear cell invasion precede specific necrosis of human melanoma and sarcoma treated by intravascular high-dose tumour necrosis factor alpha (TNFα). Int J Cancer 1994; 57: 656-663.
41. Nooijen PTGA, Eggermont AMM, Schalkwijk L et al. Complete response of melanoma in-transit metastasis after isolated limb perfusion with tumor necrosis factor-alpha and melphalan without massive tumor necrosis: clinical and histopathological study of the delayed-type reaction patterns. Cancer Res 1998; 58: 4880-4887.
42. De Wilt JHW, ten Hagen TLM, de Boeck G et al. Tumour Necrosis Factor alpha increases melphalan concentration in tumour tissue after isolated limb perfusion. Br J Cancer 2000; 82: 1000-1003.
43. Veen vd AH, Wilt de JHW, Eggermont AMM et al. TNF-α augments intratumoural concentration of doxorubicin in TNF-α-based isolated limb perfusion in rat sarcoma models and enhances antitumour effects. Br J Cancer 2000; 82: 973-980.
44. van Etten B, de Vries M, van Ijken M et al. Degree of tumour vascularity correlates with drug accumulation and tumour response upon TNF-based isolated hepatic perfusion. Br J Cancer 2003; 87: 314-319.
45. DeWilt JHW, Manusama ER, van Tiel ST et al. Prerequisites for effective isolated limb perfusion using tumour necrosis factor-alpha and melphalan in rats. Br J Cancer 1999; 80: 161-166.
46. Seynhaeve ALB, de Wilt JHW, van Tiel SA et al. Combination of Actinomycin D with TNF-α in Isolated Limb Perfusion results in improved tumour response in soft tissue sarcoma-bearing rats but is accompanied by severe dose limiting local toxicity. Br J Cancer 2002; 86: 1174-1179.
47. DeWilt JHW, Manusama ER, van Etten B et al. Inhibition of nitric oxide synthesis by L-NAME results in synergistic antitumour activity with melphalan and tumour necrosis factor-alpha-based isolated limb. Br J Cancer 2000; 83: 1176-1182.
48. Brunstein F, Hoving S, van Tiel S et al. Synergistic antitumor activity of histamine in combination with chemotherapy in the regional treatment of soft tissue sarcomas. Eur J Cancer Suppl 2003; 1: 699.
49. Ten Hagen TLM, Lejeune FJ, Eggermont AMM. TNF is here to stay - revisited. Trends Immunol 2001; 22: 127-129.
50. Eggermont AMM, De Wilt JHW, Ten Hagen TLM. Current uses of isolated limb perfusion in the clinic and a model system for new strategies. Lancet Oncol 2003; 4: 429-437.